Vuity Availability Update: What Patients Need to Know in 2026

If you're searching for the latest update on Vuity availability, here's what you need to know: as of 2026, Vuity (pilocarpine hydrochloride ophthalmic solution 1.25%) is not listed as an FDA-designated drug shortage. However, patients across the country are still encountering difficulty filling their Vuity prescriptions at local pharmacies.

Understanding why — and what to do about it — is the difference between giving up on a medication that could improve your quality of life and actually getting it filled.

Current Vuity Status in 2026: Not an Official Shortage

The FDA maintains a public drug shortage database. As of early 2026, Vuity is not included. This means the manufacturer — Allergan, an AbbVie company — has not formally reported a supply disruption, and distribution to wholesalers is occurring. The product is being manufactured and shipped.

But 'not in official shortage' doesn't mean 'easy to find at your corner pharmacy.' Here's the disconnect:

Why Patients Still Struggle to Get Vuity in 2026

Not routinely stocked: Vuity is a specialty ophthalmic medication that most pharmacies don't keep on their shelves because demand was relatively modest when it first launched in 2021.

No insurance reimbursement: Since most insurance plans — including Medicare — don't cover Vuity, pharmacies have less financial incentive to maintain inventory.

Growing awareness: With two new competing presbyopia drops (Qlosi and Vizz) entering the market in 2025, overall patient interest in this drug class has grown. Some pharmacies are adjusting their stocking, but it takes time.

Generic launch impact: A generic pilocarpine 1.25% launched in August 2025. As generics enter the supply chain, brand-name stocking decisions may shift at some retailers.

What Has Changed for Vuity Patients in 2025–2026?

Several meaningful developments have occurred for Vuity patients:

Twice-daily dosing approved (2023): The FDA approved a second daily dose option for Vuity — you can now take a second drop 3-6 hours after your first, extending coverage to approximately 9 hours.

Generic available (August 2025): A lower-cost generic pilocarpine 1.25% became commercially available, helping reduce costs for patients.

New competitors entered the market: Qlosi (pilocarpine 0.4%, FDA-approved 2023, available April 2025) and Vizz (aceclidine 1.44%, FDA-approved July 2025, available October 2025) give patients more presbyopia treatment options if Vuity is unavailable.

Is Vuity Getting Harder or Easier to Find?

The overall trajectory is positive. With a generic now available and growing awareness of presbyopia drops, Vuity and its equivalents are slowly becoming more accessible. Larger pharmacies are stocking it more reliably than they did in 2021-2022. However, smaller or rural pharmacies may still struggle with inventory.

What Should You Do If You Can't Find Vuity Right Now?

Use medfinder to locate pharmacies in your area that currently have it in stock

Ask your pharmacist to check if the generic pilocarpine 1.25% is available (same drug, potentially better-stocked)

Ask your eye doctor about Qlosi or Vizz if Vuity remains consistently unavailable

Consider mail-order pharmacy for a reliable ongoing supply

The Takeaway for 2026

Vuity is not in an FDA-designated shortage, but availability challenges are real and persist in 2026. The good news: there are more options than ever — a generic, two competing prescriptions, and services like medfinder to help you locate it. If you're exploring alternatives, see our guide on alternatives to Vuity for a full breakdown.